Following this logic, the Limiting AKI Progression in Sepsis trial30,31 was designed to evaluate the application of these bundles guided by serial measurements of TIMP-2 × IGFBP7 in patients with sepsis who did not have KDIGO stage 2 or 3 disease AKI at enrollment. This evidence concerns the gene TIMP2 and acute kidney injury.